Nicox S.A. (NYSE Euronext Paris: COX) is attending the 2013 International Vision
Expo & Conference, taking place from October 3 to 5, 2013 in Las Vegas, Nevada,
United States. Nicox can be found at booth number MS2057.

Nicox will have several members of its US operational team in attendance
presenting AdenoPlus(®), a rapid point-of-care diagnostic test that aids in the
differential diagnosis of acute conjunctivitis. AdenoPlus(®) was launched by
Nicox in the US in October 2012
...................................

About Nicox

Nicox  (Bloomberg:  COX:FP,  Reuters:  NCOX.PA)  is creating a new international
player  in  the  ophthalmic  market  by  building  a  diversified  portfolio  of
innovative  therapies  and  diagnostic  tools.  With  a  heritage of scientific,
business  development and  commercial expertise,  the Nicox  team is  focused on
developing  and marketing novel pharmaceuticals  and diagnostic devices that can
help  people  to  enhance  their  sight.  In  the  United  States, Nicox markets
AdenoPlus(®),  a test for the differential diagnosis of acute conjunctivitis in-
licensed from RPS(®).

The  Company's pipeline  includes latanoprostene  bunod, a  novel drug-candidate
based  on Nicox's proprietary nitric oxide (NO)-donating R&D platform, developed
in  collaboration with Bausch + Lomb for the potential treatment of glaucoma and
ocular hypertension. Further NO-donating compounds are under development in non-
ophthalmic  indications, notably through partners, including Merck (known as MSD
outside the United States and Canada).

Nicox  S.A.  is  headquartered  in  France  and  is  listed  on  Euronext  Paris
(Compartment B: Mid Caps). For more information please visit www.nicox.com.

...................................
This  communication may contain certain forward-looking statements. Although the
Company  believes its  expectations are  based on  reasonable assumptions, these
forward-looking  statements  are  subject  to  numerous risks and uncertainties,
which  could cause actual results to differ materially from those anticipated in
the forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are
presented  in the 4th chapter of the  « Document de référence, rapport financier
annuel  et rapport de gestion 2012 » filed  with the French Autorité des Marchés
Financiers   (AMF)   on   March   22, 2013 and   available  on  Nicox's  website
(www.nicox.com) and on the AMF's website (www.amf-france.org).
...................................

Contacts
Nicox           Gavin Spencer | Executive Vice President Corporate Development
                Tel +33 (0)4 97 24 53 00 | communications@nicox.com



Media Relations FTI Consulting

Europe          Julia Phillips | D+44 (0)20 7269 7187 | M +44 (0) 7770 827 263
                Julia.Phillips@fticonsulting.com

                Stephanie Cuthbert | D +44 (0)20 3077 0458 | M +44 (0)
                7843 080947
                Stephanie.Cuthbert@fticonsulting.com

                Mo Noonan | D +44 (0)20 7269 7116 | M +44 (0)7876 444 977
                Mo.Noonan@fticonsulting.com



Nicox attends Vision Expo West 2013 in Las Vegas: http://hugin.info/143509/R/1732009/579357.pdf

[HUG#1732009]
Cox Communications (NYSE:COX)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Cox Communications Charts.
Cox Communications (NYSE:COX)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Cox Communications Charts.